Fabry Disease Treatment Market: By Treatment (Enzyme Replacement Therapy, Oral Chaperone Therapy, and Others), By Route of Administration (Oral Route and Intravenous Route), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Latin America, and MEA)

Fabry Disease Treatment Market size was valued at USD 2,491.2 million in 2022 and is expected to grow at a 7.8% CAGR from 2023 to 2029. Fabry disease is also known as alpha galactosidase-A deficiency disease. Fabry disease is a very rare inherited disorder resulting from the building up of a particular type of fat such as globotriaosylceramide within the body cells. It gets initiated in childhood and symptoms can be observed such as cluster formations, red spots on the skin, concurrent episodes of pain in hands and feet, and impairment in hearing. The increasing prevalence of Fabry disease across the globe along with the growing awareness about the disease and its treatment is expected to drive the Fabry disease treatment market growth. according to the National Fabry Disease Foundation, every year “April” is observed as Fabry Disease Awareness Month. In addition, increasing research and development in diagnosis and treatment procedures such as enzyme replacement therapy, chaperone therapy, and small molecule therapy are expected to boost the market growth over the forecast period. furthermore, growing investments by biopharmaceutical companies to develop novel and effective therapy and investments in gene therapy are expected to further propel the Fabry disease treatment market strategies over the forecast period. however, the high cost of treatment, late diagnosis, and limited market access to diagnostic tests and treatment in developing countries are expected to hinder the growth of the Fabry disease treatment market, only a few patients suffering from rare diseases were able to get an appointment with a medical provider.

Fabry Disease Treatment Market Key Developments:

• In August 2022, Amicus Therapeutics got approval for their product Galafold from the European Commission For long-term treatment of Fabry disease in above 12 years with amenable mutation.